u/diego_szabo

Went back on after eight months away. Nobody here made me feel bad about it, which mattered more than I expected.

Asked here what the difference was between the imaging and biopsy endpoints and got a genuinely excellent answer.

Disagree that this is a discrepancy. 99.3% against a claimed 99.0% is inside ordinary inter-lab variance in either direction.

Correcting myself: I quoted net peptide content against somebody else’s area percent. Not a comparison.

The template is vendor, compound, batch, service, claim, result, and who paid. Every one of those fields exists because a result missing it has been argued about here before.

Cosigning on saying who paid.

This is why the template has a batch field. Without it the result is about a vial nobody can identify.

date of analysis matters as much as the number

Appetite is the proximal effect and weight is the lagging integrated outcome, which is why watching appetite gives you an earlier and more honest signal.

Retitled — the original stated a discrepancy the numbers do not show.

Agreed — and two services on one batch is the strongest thing any of us can produce individually.

Interval stretching lowers the trough concentration while keeping the dose; dose reduction lowers the level while keeping the rhythm. They are different interventions with different subjective profiles.

Yes. Two services on the same batch is the strongest thing an individual member can produce, and it is not expensive.

Chain of custody is why member-funded testing is worth more than a supplied certificate: the vial tested is the vial that arrived at a member’s door.

Cosigning on the glucagon arm. It is the mechanistic thread that connects the hepatic and the metabolic effects.

Small fix — you have described interval stretching and called it a taper. The exposure profiles differ.

The template is vendor, compound, batch, service, claim, result, and who paid. Every one of those fields exists because a result missing it has been argued about here before.

How many separate lots does your series cover?

biopsy-confirmed is not the same as imaging-suggested

phase 2 in liver disease is a different evidence question from weight

vikram_mbeki is right that biopsy and imaging endpoints are not interchangeable.

Small fix — same supplier, different lot. The two rows in the log are not the same batch.

Histological endpoints in this field are scored on biopsy: resolution of steatohepatitis without worsening of fibrosis, or improvement in fibrosis without worsening of steatohepatitis. Both are harder to achieve and to interpret than an imaging surrogate.

Not convinced by the comparison. Different services, different gradients, and you are treating one as ground truth.

one result is a data point, agreement between two services is evidence

Interval stretching lowers the trough concentration while keeping the dose; dose reduction lowers the level while keeping the rhythm. They are different interventions with different subjective profiles.

three lots beats three tests on one lot

Disagree that this is a discrepancy. 98.0% against a claimed 97.5% is inside ordinary inter-lab variance in either direction.

Area percent and net peptide content are different measurements and most reports give one. Quote which, or the comparison downstream is meaningless.

results without method are gossip with decimals

Same. The BCH results have been sitting in a tight band across lots, which is the useful shape.

Right, and the trial titration was slow for reasons that are visible in the tolerability tables.

What a result posted here is actually worth, and how to make yours worth more.

edit_for_clarity is right that the band matters more than the peak. Consistency across lots is the finding.

Area percent and net peptide content are different measurements and most reports give one. Quote which, or the comparison downstream is meaningless.